Aidite Qinhuangdao Technology (301580) Fundamentals 2026 — P/E 28.2x, Revenue Analysis | SniperIQ
Aidite Qinhuangdao Technology (301580) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of ¥8.0B, trading at ¥53.83 on the SHZ. This SniperIQ fundamentals page covers Aidite Qinhuangdao Technology's valuation (P/E 28.2x, P/B 2.6x), profitability (net margin 18.7%), revenue (¥1.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aidite Qinhuangdao Technology's market cap?
Aidite Qinhuangdao Technology (301580) has a market capitalization of approximately ¥8.0B, trading at ¥53.83 on the SHZ. Market cap moves with the live share price.
What is Aidite Qinhuangdao Technology's P/E ratio?
Aidite Qinhuangdao Technology's trailing twelve-month P/E ratio is 28.2x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aidite Qinhuangdao Technology?
Aidite Qinhuangdao Technology runs a net profit margin of 18.7%, a gross margin of 53.7%, and an operating margin of 20.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aidite Qinhuangdao Technology generate?
Aidite Qinhuangdao Technology reported revenue of ¥1.0B for fiscal year 2025, with net income of ¥196M and earnings per share (EPS) of 1.84. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aidite Qinhuangdao Technology pay a dividend?
Aidite Qinhuangdao Technology offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Aidite Qinhuangdao Technology financially healthy?
Aidite Qinhuangdao Technology carries a debt-to-equity ratio of 0.02x and a current ratio of 8.43x, with a market beta of 0.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aidite Qinhuangdao Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aidite Qinhuangdao Technology (301580) the key facts are: market cap ¥8.0B, P/E 28.2x, revenue ¥1.0B, 52-week range 29.77143-87.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aidite Qinhuangdao Technology's full fundamentals live
Get Aidite Qinhuangdao Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.